Does preexisting immuncompromised status prevent mortality in COVID-19 patients: friend or foe?
D. Vezir (ISTANBUL, Turkey), S. Olgun Yildizeli (ISTANBUL, Turkey), D. Kocakaya (ISTANBUL, Turkey), Z. Mercanci (ISTANBUL, Turkey), B. Balcan (ISTANBUL, Turkey), C. Çinar (ISTANBUL, Turkey), E. Eryüksel (ISTANBUL, Turkey), S. Karakurt (ISTANBUL, Turkey)
Source: International Congress 2022 – Clinical problems in respiratory medicine: 2
Session: Clinical problems in respiratory medicine: 2
Session type: Thematic Poster
Number: 2365
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Vezir (ISTANBUL, Turkey), S. Olgun Yildizeli (ISTANBUL, Turkey), D. Kocakaya (ISTANBUL, Turkey), Z. Mercanci (ISTANBUL, Turkey), B. Balcan (ISTANBUL, Turkey), C. Çinar (ISTANBUL, Turkey), E. Eryüksel (ISTANBUL, Turkey), S. Karakurt (ISTANBUL, Turkey). Does preexisting immuncompromised status prevent mortality in COVID-19 patients: friend or foe?. 2365
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|